Qiagen N v   (QGEN)
Other Ticker:  
Price: $40.0000 $0.53 1.343%
Day's High: $40.14 Week Perf: 0.83 %
Day's Low: $ 39.64 30 Day Perf: -9.38 %
Volume (M): 1,108 52 Wk High: $ 47.70
Volume (M$): $ 44,316 52 Wk Avg: $43.06
Open: $39.64 52 Wk Low: $34.74

 Market Capitalization (Millions $) 9,225
 Shares Outstanding (Millions) 231
 Employees 5,700
 Revenues (TTM) (Millions $) 1,901
 Net Income (TTM) (Millions $) 341
 Cash Flow (TTM) (Millions $) -63
 Capital Exp. (TTM) (Millions $) 163

Qiagen N V

Qiagen N.V. is a biotech company that provides molecular diagnostics and life science research services.
The company develops and markets sample and assay technologies, including PCR, Sequencing, and Genomics, to customers in the academic research, pharma and biotech, healthcare, and environmental testing industries.
Qiagen Nv's products and services enable scientists to extract and process DNA, RNA, and other types of biological samples, perform gene expression analysis, and identify biomarkers for disease diagnosis and therapy.
Qiagen Nv was founded in 1984 and is headquartered in Venlo, Netherlands, with operations across the world.

   Company Address: Hulsterweg 82 Venlo 5912
   Company Phone Number:    Stock Exchange / Ticker: NYSE QGEN


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


QIAGEN N.V. Unveils Impressive Q1 2024 Results, Empowering Global Health through Innovative Solutions

Published Tue, Apr 9 2024 1:49 PM UTC

Venlo, The Netherlands, April 09, 2024 ?? QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA), a leading provider of innovative molecular testing solutions, has just released its highly anticipated financial results for the first quarter of 2024. The company's strong performance underscores its unwavering commitment to global health amid challenging times.QIAGEN's Q1 20...


Revolutionizing Oncology: QIAGEN's Novel Tools Propel Cancer Research Into Uncharted Territories

Published Wed, Apr 3 2024 8:05 PM UTC

Recently, QIAGEN, an established global provider of molecular diagnostics and sample preparation technologies, demonstrated its commitment to advance cancer research by showcasing its latest product launches at the AACR Annual Meeting 2024. The new offerings reflect a breakthrough in medical research and present great promise for the future of oncology.QIAGEN's QIAcuity dPCR...


Rokk Energy Technologies and Northern Smilodon Energy Forge Strategic Partnership to Enhance Resource Recovery and Reduce Environmental Footprint in Unconventional Resource Development

Published Mon, Mar 25 2024 3:00 PM UTC

Calgary-based companies Rokk Energy Technologies and Northern Smilodon Energy have recently announced a strategic relationship aimed at harnessing the potential of Rokk's Pad-Free advanced drilling and completion system. By leveraging this technology, the two companies envision optimizing hydrocarbon resource recovery, mitigating emissions from oil-field operations, and mini...


Celebrating a New Era of Automotive Excellence: Bentley Motors Receives Warrant of Automotive Distinction from the McWhorter Family Trust

Published Mon, Mar 18 2024 7:56 PM UTC

In a groundbreaking announcement, the McWhorter Family Trust has forged a strategic partnership with Bentley Motors, marking a significant milestone in the realm of automotive excellence. Recognizing Bentley's unrivaled dedication to luxury, innovation, and craftsmanship, the Trust has bestowed the prestigious emblem of automotive distinction upon the renowned British automa...

Qiagen N V

Headline: Qiagen N V Sees Significant Decrease in Revenue and Income in Fourth Quarter of 2023

The recent financial report for Qiagen N V paints a grim picture for the company's financial health. The company's income fell by a staggering -19.57% in the October to December 31 2023 period, dropping to $1.48 per share from $1.84 a year before. This significant decrease in income is alarming and raises concerns about the company's ability to generate profits in the future.
Furthermore, Qiagen N V's revenue took a hit as well, declining by -8.67% to $1.90 billion from $2.08 billion in the same reporting period a year ago. This sharp decrease in revenue is a clear indication that the company is facing challenges in maintaining its market share and profitability. The bottom-line of $341.303 million in the October to December 31, 2023 period also fell by -19.35% from $423.211 million in the corresponding period a year before, further highlighting the company's financial struggles.


Qiagen N V's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Qiagen N V does not provide revenue guidance.

Earnings Outlook
Qiagen N v does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com